FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1110-1115 October 27, 1994 Number 17 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Tacrolimus (FK 506), a macrolide compound isolated from a bacterium, is a potent immunosuppressant with activity in solid-organ transplants. Most immunosuppressive regimens for liver transplantation are based on cyclosporine.

Methods We conducted an open-label, randomized, multicenter trial to compare the efficacy and safety of tacrolimus-based and cyclosporine-based immunosuppressive regimens for patients receiving a first liver transplant. A total of 478 adults and 51 children ( 12 years of age) were randomly assigned at the time of transplantation to receive tacrolimus (n = 263) or cyclosporine (n = 266) and were followed for one year. The primary end points were patient and graft survival at one year. The secondary end points were the incidence of acute rejection, corticosteroid-resistant rejection, and refractory rejection (continued rejection after two courses of corticosteroids and an intervening course of muromonab-CD3).

Results According to Kaplan-Meier analysis, actuarial patient-survival rates at day 360 were 88 percent for both the tacrolimus and cyclosporine groups (P = 0.85; 95 percent confidence interval for the difference, -5.4 to 6.6 percent), and graft-survival rates were 82 percent and 79 percent, respectively (P = 0.55; 95 percent confidence interval for the difference, -4.8 to 9.7 percent). Acute rejection occurred in 154 patients in the tacrolimus group and 173 patients in the cyclosporine group (P<0.002), corticosteroid-resistant rejection occurred in 43 and 82 patients, respectively (P<0.001), and refractory rejection occurred in 6 and 32 patients, respectively (P<0.001). Tacrolimus was associated with a higher incidence of adverse events requiring withdrawal from the study, primarily nephrotoxicity and neurotoxicity; 37 patients in the tacrolimus group and 13 in the cyclosporine group discontinued the study because of adverse events (P<0.001).

Conclusions After one year, immunosuppressive regimens based on tacrolimus and cyclosporine were comparable in terms of patient and graft survival. Tacrolimus was associated with significantly fewer episodes of acute, corticosteroid-resistant, or refractory rejection, but substantially more adverse events requiring discontinuation of the drug.

Source Information

Dr. Klintmalm assumes full responsibility for the overall content and integrity of the manuscript.Members of the U.S. Multicenter FK506 Liver Study Group are listed in the Appendix.

Address reprint requests to Dr. Goran B. Klintmalm at Baylor University Medical Center, 3500 Gaston Ave., Dallas, TX 75246.

Full Text of this Article

This article has been cited by other articles:

• Plaumann, S., Blume, R., Borchers, S., Steinfelder, H. J., Knepel, W., Oetjen, E. (2008). Activation of the Dual-Leucine-Zipper-Bearing Kinase and Induction of {beta}-Cell Apoptosis by the Immunosuppressive Drug Cyclosporin A. Mol. Pharmacol. 73: 652-659 [Abstract] [Full Text]  
• O'Riordan, A., Wong, V., McCormick, P. A., Hegarty, J. E., Watson, A. J. (2006). Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 21: 2630-2636 [Abstract] [Full Text]  
• Gee, I, Alexander, G (2005). Liver transplantation for hepatitis C virus related liver disease. Postgrad. Med. J. 81: 765-771 [Abstract] [Full Text]  
• Halloran, P. F. (2004). Immunosuppressive Drugs for Kidney Transplantation. NEJM 351: 2715-2729 [Full Text]  
• Di Cosmo, N., Vajro, P., Debray, D., Valerio, G., Giugliano, M., Buono, P., Franzese, A. (2004). Normal {beta}-Cell Function in Post-Liver Transplantation Diabetes Treated With Tacrolimus. Diabetes Care 27: 1837-1838 [Full Text]  
• Taylor, P. J, Kubler, P. A, Lynch, S. V, Allen, J., Butler, M., Pillans, P. I (2004). Effect of Atorvastatin on Cyclosporine Pharmacokinetics in Liver Transplant Recipients. The Annals of Pharmacotherapy 38: 205-208 [Abstract] [Full Text]  
• Oetjen, E., Baun, D., Beimesche, S., Krause, D., Cierny, I., Blume, R., Dickel, C., Wehner, S., Knepel, W. (2003). Inhibition of Human Insulin Gene Transcription by the Immunosuppressive Drugs Cyclosporin A and Tacrolimus in Primary, Mature Islets of Transgenic Mice. Mol. Pharmacol. 63: 1289-1295 [Abstract] [Full Text]  
• Adams, A. B., Shirasugi, N., Durham, M. M., Strobert, E., Anderson, D., Rees, P., Cowan, S., Xu, H., Blinder, Y., Cheung, M., Hollenbaugh, D., Kenyon, N. S., Pearson, T. C., Larsen, C. P. (2002). Calcineurin Inhibitor-Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates. Diabetes 51: 265-270 [Abstract] [Full Text]  
• Helderman, J. H., Goral, S. (2002). Gastrointestinal Complications of Transplant Immunosuppression. J. Am. Soc. Nephrol. 13: 277-287 [Full Text]  
• Lunz, J. G. III, Contrucci, S., Ruppert, K., Murase, N., Fung, J. J., Starzl, T. E., Demetris, A. J. (2001). Replicative Senescence of Biliary Epithelial Cells Precedes Bile Duct Loss in Chronic Liver Allograft Rejection : Increased Expression of p21WAF1/Cip1 as a Disease Marker and the Influence of Immunosuppressive Drugs. Am. J. Pathol. 158: 1379-1390 [Abstract] [Full Text]  
• Nash, R. A., Antin, J. H., Karanes, C., Fay, J. W., Avalos, B. R., Yeager, A. M., Przepiorka, D., Davies, S., Petersen, F. B., Bartels, P., Buell, D., Fitzsimmons, W., Anasetti, C., Storb, R., Ratanatharathorn, V. (2000). Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96: 2062-2068 [Abstract] [Full Text]  
• Kawai, T., Shimada, A., Kasuga, A. (2000). FK506-Induced Autoimmune Diabetes. ANN INTERN MED 132: 511-511 [Full Text]  
• Shimoyama, M., Hayashi, D., Takimoto, E., Zou, Y., Oka, T., Uozumi, H., Kudoh, S., Shibasaki, F., Yazaki, Y., Nagai, R., Komuro, I. (1999). Calcineurin Plays a Critical Role in Pressure Overload-Induced Cardiac Hypertrophy. Circulation 100: 2449-2454 [Abstract] [Full Text]  
• Mazariegos, G. V., Reyes, J. (1999). What's New in Pediatric Organ Transplantation. Pediatr. Rev. 20: 363-375 [Full Text]  
• Grimbert, P., Azema, C., Pastural, M., Dhamane, D., Remy, P., Salomon, L., Schortgen, F., Baron, C., Lang, P. (1999). Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient. Nephrol Dial Transplant 14: 2489-2491 [Full Text]  
• Shirbacheh, M. V., Jones, J. W., Harralson, T. A., Edelstein, J., Tecimer, T., Breidenbach, W. C., Jevans, A. W., Maldonado, C., Barker, J. H., Gruber, S. A. (1999). Pharmacokinetics of Intra-arterial Delivery of Tacrolimus to Vascularly Isolated Rabbit Forelimb. J. Pharmacol. Exp. Ther. 289: 1196-1201 [Abstract] [Full Text]  
• Siemann, G., Blume, R., Grapentin, D., Oetjen, E., Schwaninger, M., Knepel, W. (1999). Inhibition of Cyclic AMP Response Element-Binding Protein/Cyclic AMP Response Element-Mediated Transcription by the Immunosuppressive Drugs Cyclosporin A and FK506 Depends on the Promoter Context. Mol. Pharmacol. 55: 1094-1100 [Abstract] [Full Text]  
• van den Berg, J W K, Postma, D S, Koëter, G H, van der Bij, W (1999). New immunosuppressive drugs and lung transplantation: last or least?. Thorax 54: 550-553 [Full Text]  
• BIZOLLON, T, DUCERF, C, TREPO, C, MUTIMER, D (1999). Hepatitis C virus recurrence after liver transplantation. Gut 44: 575-578 [Abstract] [Full Text]  
• Takeda, Y., Miyamori, I., Furukawa, K., Inaba, S., Mabuchi, H. (1999). Mechanisms of FK 506–Induced Hypertension in the Rat. Hypertension 33: 130-136 [Abstract] [Full Text]  
• Hunt, S. A. (1998). Current Status of Cardiac Transplantation. JAMA 280: 1692-1698 [Abstract] [Full Text]  
• Plevak, D. J., De Ruyter, M. L. (1998). Intensive Care of the Intra-Abdominal Organ Transplant Recipient. SEMIN CARDIOTHORAC VASC ANESTH 2: 155-165 [Abstract]  
• Strouse, T. B., El-Saden, S. M., Glaser, N. E.M., Bonds, C., Ayars, N., Busuttil, R. W. (1998). Immunosuppressant Neurotoxicity in Liver Transplant Recipients: Clinical Challenges for the Consultation-Liaison Psychiatrist. Psychosomatics 39: 124-133 [Abstract] [Full Text]  
• Berlakovich, G. A., Rockenschaub, S., Taucher, S., Kaserer, K., Muhlbacher, F., Steiniger, R. (1998). Underlying Disease as a Predictor for Rejection After Liver Transplantation. Arch Surg 133: 167-172 [Abstract] [Full Text]  
• Wang, M.-S., Zeleny-Pooley, M., Gold, B. G. (1997). Comparative Dose-Dependence Study of FK506 and Cyclosporin A on the Rate of Axonal Regeneration in the Rat Sciatic Nerve. J. Pharmacol. Exp. Ther. 282: 1084-1093 [Abstract] [Full Text]  
• Steffen, R., Wyllie, R., Kay, M., Kyllonen, K., Gramlich, T., Petras, R. (1997). Autoimmune Enteropathy in a Pediatric Patient: Partial Response to Tacrolimus Therapy. CLIN PEDIATR 36: 295-299  
• Pham, S. M., Kormos, R. L., Hattler, B. G., Kawai, A., Tsamandas, A. C., Demetris, A. J., Murali, S., Fricker, F. J., Chang, H. C., Jain, A. B., Starzl, T. E., Hardesty, R. L., Griffith, B. P. (1996). A PROSPECTIVE TRIAL OF TACROLIMUS (FK 506) IN CLINICAL HEART TRANSPLANTATION: INTERMEDIATE-TERM RESULTS. J. Thorac. Cardiovasc. Surg. 111: 764-772 [Abstract] [Full Text]  
• Gane, E. J., Portmann, B. C., Naoumov, N. V., Smith, H. M., Underhill, J. A., Donaldson, P. T., Maertens, G., Williams, R. (1996). Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. NEJM 334: 815-821 [Abstract] [Full Text]  
• McNair, A N B, Tibbs, C J, Williams, R (1995). Recent Advances: Hepatology. BMJ 311: 1351-1355 [Full Text]  
• Calne, R. Y. (1994). Immunosuppression in Liver Transplantation. NEJM 331: 1154-1155 [Full Text]